Nová doporučení pro akutní koronární syndrom a kritika definice infarktu myokardu na Sjezdu Evropské kardiologické společnosti v Amsterodamu 2023

Jan F. Vojáček

Interv Akut Kardiol. 2023;22(3):107-108 | DOI: 10.36290/kar.2023.030  

Brachial artery injury in Al-Emamain Al-Kadhymain Medical City, Baghdad, Iraq: a single-center clinical experience

Noor Abbas Hummadi Fayadh, Abbas Jaafar Khaleel Al-Anbari, Bassam Maddah H. Al-Alosi

Interv Akut Kardiol. 2023;22(3):109-113 | DOI: 10.36290/kar.2022.033  

Aims: To identify the most common causes, associated injuries, and management approaches in the case of brachial artery injuries. Methods: This was a retrospective survey conducted in Al-Emamain Al-Kadhymain Medical City, Baghdad-Iraq, which included 104 patients who were diagnosed to have brachial artery injury during the period from January 2015 to April 2021. The evaluated factors included demographic data, site of injury, causes of injury, associated injury, type of treatment, and complications. Results: One hundred and four patients were registered in the present study. The majority were males (86.7%) and half of the cases were in the 31-40...

Treatment options of in­‑stent restenosis: mini review

Rana Zhafira Amanda, Natasha Anindhia Harsas, Sidhi Laksono Purwowiyoto

Interv Akut Kardiol. 2023;22(3):122-128 | DOI: 10.36290/kar.2022.032  

In­‑stent restenosis (ISR) is the leading cause of the need for reintervention after percutaneous coronary intervention (PCI). Lumen diameter reduction may occur due to early elastic return, vascular remodelling, or aggressive neointimal hyperplasia in the luminal surface of the stent. Recent data also suggest that a newly occurring atherosclerotic process called „neoatherosclerosis“ can play an essential role in the development of ISR. Numerous studies have shown a high incidence of acute coronary syndrome (ACS) as a clinical manifestation of ISR and its association with increased mortality and morbidity. Stent improvements, novel...

Isolated tricuspid regurgitation: a case report and overview of the issue

Zuzana Hlubocká, Michaela Zemková, David Zemánek

Interv Akut Kardiol. 2023;22(3):129-135 | DOI: 10.36290/kar.2023.024  

Isolated tricuspid regurgitation is the second most common cause of secondary tricuspid insufficiency. It results from tricuspid annulus dilatation leading to malcoaptation in patients without significant left-sided heart disease or pulmonary hypertension. Isolated tricuspid regurgitation typically occurs in elderly patients with a high prevalence of atrial fibrillation and severe right atrial dilatation; therefore, it is also referred to as atrial tricuspid regurgitation. We present a case of an 85-year-old woman with symptomatic severe isolated tricuspid regurgitation. Imaging methods (transthoracic and transoesophageal echocardiography, cardiac...

Pericardial cyst: an incidental culprit

Mariana Santos, Margarida Figueiredo, Mariana Coelho, Halder Santos, Samuel Almeida, Sofia B. Paula

Interv Akut Kardiol. 2023;22(3):142-144 | DOI: 10.36290/kar.2023.010  

Complex intervention with intravenous P2Y₁₂ inhibitor

Vojtěch Brázdil, Martin Hudec, Martin Poloczek

Interv Akut Kardiol. 2023;22(3):136-137 | DOI: 10.36290/kar.2023.027  

Kangrelor represents the only intravenous inhibitor of the platelet receptor P2Y₁₂ with clinically proven effectiveness in reducing ischemic complications of percutaneous coronary intervention (PCI). According to the Summary of Product Characteristics (SPC), Kangrelor is recommended for patients undergoing PCI who have not been treated with an oral P2Y₁₂ inhibitor or for whom this therapy is not possible or suitable. In the following case study, a high-risk patient undergoing a complex interventional procedure using this preparation will be presented (1).

Long-term effect of fixed-dose combination of perindopril and bisoprolol in a patient with ischemic heart disease after an episode of heart failure with reduced left ventricular ejection fraction: an example from practice

Filip Málek

Interv Akut Kardiol. 2023;22(3):138-141 | DOI: 10.36290/kar.2023.026  

Angiotensin-converting enzyme inhibitors and beta blockers have an additive effect on the reduction in mortality and morbidity in patients with heart failure and reduced ejection fraction regardless of the etiology of cardiac dysfunction. Fixed-dose combination of perindopril and bisoprolol is advantageous, improving patient adherence to treatment when a combination of a beta blocker with an ACE inhibitor is indicated. We present a case report of a patient after an episode of heart failure due to ischemic heart disease in whom long-term treatment with fixed-dose combination of perindopril and bisoprolol was associated with an improvement in left ventricular...

When two valves fail, it's time for a third one (transcatheter valve­‑in­‑valve implantation)

Zuzana Komorová, Jan Sitar, Jiří Seménka, Ladislav Groch, Lenka Špinarová, Karin Ďurčanská

Interv Akut Kardiol. 2023;22(3):201-205 | DOI: 10.36290/kar.2023.015  

This case report depicts a 90-year-old patient with exertional dyspnea of NYHA class III following bioprosthetic replacement of the aortic valve (Sorin Perceval S sutureless). She developed a relatively early (6 years), highly significant (AVA 0.3 cm²) and symptomatic degeneration of bioprosthesis with severe left ventricular depression and a left ventricular ejection fraction of 25%. At a heart center, the patient underwent a valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) procedure using the 23-mm CoreValve Evolut R valve, resulting in an early optimal tonometric, angiographic, echocardiographic and clinical effect. The...

Technology of catheter ablation of atrial fibrillation using pulsed field

Martin Mudroch, Štěpán Královec, Jan Petrů, Petr Neužil

Interv Akut Kardiol. 2023;22(3):145-150 | DOI: 10.36290/kar.2023.022  

Catheter ablation of atrial fibrillation using radiofrequency energy has been the gold standard until these days. Nevertheless, there are limitations associated with the application of thermal energy such as damage to collateral structures, time-consuming nature, and, in particular, frequent recurrences of both atrial fibrillation and atrial tachycardias. Therefore, it was essential to find a brand new method with a better safety and efficiency profile. Promising results have been obtained with methods using pulsed field based on the principles of irreversible electroporation which, in comparison with the methods used so far that have a thermal effect...

The DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) Trial

Jindřich Špinar, Lenka Špinarová

Interv Akut Kardiol. 2023;22(3):151-154 | DOI: 10.36290/kar.2023.009  

The results of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial were presented at the 2022 European Cardiology Congress. The trial tested the effect of dapagliflozin in patients with heart failure and preserved ejection fraction. A total of 6263 patients were randomised to placebo or dapagliflozin. Dapagliflozin significantly decreased worsening of heart failure or cardiovascular death rates. The latest data show that the mechanism of action of gliflozins is much broader than expected, especially the metabolic effect. This has been confirmed by the EMPEROR Preserved and DELIVER...